Amarin (AMRN)
(Real Time Quote from BATS)
$0.87 USD
+0.01 (1.15%)
Updated Apr 26, 2024 02:36 PM ET
3-Hold of 5 3
C Value B Growth C Momentum B VGM
Company Summary
Dublin, Ireland-based Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid, for treating cardiovascular diseases.
The company’s sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride (TG) levels (≥500 mg/dL). In December 2019, the FDA approved Vascepa to reduce cardiovascular risk (CV) in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug received approval for both indications in Europe in March 2021. Vascepa ...
Company Summary
Dublin, Ireland-based Amarin Corporation plc is a commercial-stage pharmaceutical company focused on developing therapies, especially based on omega-3 fatty acid, for treating cardiovascular diseases.
The company’s sole marketed drug, Vascepa (icosapent ethyl) is approved in the United States as an adjunct to diet for treating severe hypertriglyceridemia or elevated triglyceride (TG) levels (≥500 mg/dL). In December 2019, the FDA approved Vascepa to reduce cardiovascular risk (CV) in patients with persistent elevated triglycerides on statin therapy for LDL-C. The drug received approval for both indications in Europe in March 2021. Vascepa is marketed in Europe under the tradename of Vazkepa.
However, a district court ruled in favor of generic companies seeking approval for the generic version of Vascepa for treating hypertriglyceridemia and Amarin lost its appeal against the ruling. Generic versions of the drug have been launched by Dr. Reddy, Apotex and Teva Pharmaceuticals in the United States.
Amarin derives revenues primarily from the sale of Vascepa in the United States. The drug recorded sales of $285.3 million in 2023, down almost 22.1% year over year.
Early launches are currently underway in several European countries, including the United Kingdom, Spain and the Netherlands. The drug is also approved in Switzerland, Australia, New Zealand and Israel. The company’s partner in China has received approval for Vascepa in Hong Kong and Mainland China for the CV reduction indication.
The company reported total revenues of $306.9 million in 2023, down 17% year over year.
General Information
Amarin Corporation PLC
Iconic Offices The Greenway Block C Ardilaun Court 112 - 114 Street
DUBLIN, L2 Dublin 2
Phone: 353-1669-9020
Fax: NA
Web: http://www.amarincorp.com
Email: investor.relations@amarincorp.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Earnings Date | 5/1/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | -0.04 |
Current Year EPS Consensus Estimate | -0.14 |
Estimated Long-Term EPS Growth Rate | NA |
Earnings Date | 5/1/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 0.86 |
52 Week High | 1.49 |
52 Week Low | 0.65 |
Beta | 1.98 |
20 Day Moving Average | 1,207,184.25 |
Target Price Consensus | 1.08 |
4 Week | -3.45 |
12 Week | -28.92 |
YTD | -1.14 |
4 Week | 0.49 |
12 Week | -30.92 |
YTD | -6.59 |
Shares Outstanding (millions) | 410.67 |
Market Capitalization (millions) | 353.22 |
Short Ratio | NA |
Last Split Date | 1/18/2008 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | NA |
Change in Payout Ratio | NA |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | NA |
Trailing 12 Months | 21.50 |
PEG Ratio | NA |
vs. Previous Year | NA |
vs. Previous Quarter | 80.00% |
vs. Previous Year | -17.21% |
vs. Previous Quarter | 13.11% |
Price/Book | 0.64 |
Price/Cash Flow | NA |
Price / Sales | 1.15 |
3/31/24 | NA |
12/31/23 | -10.47 |
9/30/23 | -9.12 |
3/31/24 | NA |
12/31/23 | -6.97 |
9/30/23 | -6.09 |
3/31/24 | NA |
12/31/23 | 2.80 |
9/30/23 | 2.69 |
3/31/24 | NA |
12/31/23 | 1.80 |
9/30/23 | 1.74 |
3/31/24 | NA |
12/31/23 | -19.26 |
9/30/23 | -16.27 |
3/31/24 | NA |
12/31/23 | -19.26 |
9/30/23 | -16.27 |
3/31/24 | NA |
12/31/23 | -17.49 |
9/30/23 | -17.99 |
3/31/24 | NA |
12/31/23 | 1.35 |
9/30/23 | 1.37 |
3/31/24 | NA |
12/31/23 | 0.59 |
9/30/23 | 0.59 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |